CORC

在结果中检索

CORC

浏览/检索结果: 共9条，第1-9条 帮助

已选(0)清除 条数/页：   排序方式：
In vitro study of anti-ER positive breast cancer effect and mechanism of 1,2,3,4-6-pentyl-O-galloyl-beta-d-glucose . 期刊论文
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, 卷号: Vol.111, 页码: 813-820
作者:  Xiang Qiu;  Tang Juan;  Luo Qin;  Xue Jinfeng;  Tao Yexing
收藏  |  浏览/下载：4/0  |  提交时间：2019/12/13
Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival 期刊论文
BREAST CANCER RESEARCH AND TREATMENT, 2018, 卷号: 168, 期号: 3
作者:  Zhang, Ying;  Ji, Yajie;  Li, Jianwei;  Lei, Li;  Wu, Siyu
收藏  |  浏览/下载：17/0  |  提交时间：2019/12/05
Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival 期刊论文
BREAST CANCER RESEARCH AND TREATMENT, 2018, 卷号: 168, 期号: 3
作者:  Shao, Zhimin;  Zhang, Ying;  Ji, Yajie;  Li, Jianwei;  Lei, Li
收藏  |  浏览/下载：5/0  |  提交时间：2019/12/05
Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival 期刊论文
Breast cancer research and treatment, 2018, 卷号: 168, 页码: 679-686
作者:  Zhang Ying[1];  Ji Yajie[2];  Li Jianwei[3];  Lei Li[4];  Wu Siyu[5]
收藏  |  浏览/下载：5/0  |  提交时间：2019/04/24
Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival 期刊论文
BREAST CANCER RESEARCH AND TREATMENT, 2018, 卷号: 168, 期号: 3
作者:  Zhang, Ying;  Ji, Yajie;  Li, Jianwei;  Lei, Li;  Wu, Siyu
收藏  |  浏览/下载：11/0  |  提交时间：2019/12/06
Exploring the pharmacological mechanism of Yanghe Decoction on HER2-positive breast cancer by a network pharmacology approach 期刊论文
Journal of Ethnopharmacology, 2017, 卷号: 199, 页码: 68-85
作者:  Zeng, Luting*;  Yang, Kailin
收藏  |  浏览/下载：4/0  |  提交时间：2019/12/27
ER  estrogen receptor  PGR  progesterone receptor  HER  human epidermal growth factor receptor  CAM  complementary and alternative medicine  TCM  traditional Chinese medicine  YHD  Yanghe Decoction  OB  oral bioavailability  DL  drug-likeness  PPI  protein-protein interaction  GO  Gene Ontology  IGFR  insulin-like growth factor receptor  HB-EGF  heparin-binding growth factor  EGFR  epidermal growth factor receptor  PRE  progesterone response element  TGF  transforming growth factor  HDAC  histone deacetylase  CDK  cyclin dependent kinases  EMT  epithelial-mesenchymal transition  IGFBP  IGF-binding protein  FGFR  fibroblast growth factor receptor  Yanghe Decoction  HER2-positive breast cancer  Network pharmacology  Traditional Chinese medicine  Chinese medicine formulae  
Huaier extract synergizes with tamoxifen to induce autophagy and apoptosis in ER-positive breast cancer cells 期刊论文
ONCOTARGET, 2016, 卷号: 7, 期号: 18, 页码: 26003-26015
作者:  Qi, Wenwen;  Sun, Mingjuan;  Kong, Xiangnan;  Li, Yaming;  Wang, Xiaolong
收藏  |  浏览/下载：16/0  |  提交时间：2019/12/16
Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review 期刊论文
Drug Design, Development and Therapy, 2015, 卷号: 9, 页码: 5277-5285
作者:  Huang, Ruixue;  Ding, Ping;  Yang, Fei*
收藏  |  浏览/下载：15/0  |  提交时间：2019/12/03
CDH1  as a tumor suppressor gene  contributes sporadic breast cancer (BC) progression. However  the association between CDH1 hypermethylation and BC  and its clinicopathological significance remains unclear. We conducted a meta-analysis to investigate the relationship between the CDH1 methylation profile and the major clinicopathological features. A detailed literature was searched through the electronic databases PubMed  Web of Science™  and EMBASE™ for related research publications. The data were extracted and assessed by two reviewers independently. Odds ratios (ORs) with corresponding confidence intervals (CIs) were calculated and summarized respectively. The frequency of CDH1 methylation was significantly higher in invasive ductal carcinoma than in normal breast tissues (OR =5.83  95% CI 3.76–9.03  P<0.00001). CDH1 hypermethylation was significantly higher in estrogen receptor (ER)-negative BC than in ER-positive BC (OR =0.62  95% CI 0.43–0.87  P=0.007). In addition  we found that the CDH1 was significantly methylated in HER2-negative BC than in HER2-positive BC (OR =0.26  95% CI 0.15–0.44  P<0.00001). However  CDH1 methylation frequency was not associated with progesterone receptor (PR) status  or with grades  stages  or lymph node metastasis of BC patients. Our results indicate that CDH1 hypermethylation is a potential novel drug target for developing personalized therapy. CDH1 hypermethylation is strongly associated with ER-negative and HER2-negative BC  respectively  suggesting CDH1 methylation status could contribute to the development of novel therapeutic approaches for the treatment of ER-negative or HER2-negative BC with aggressive tumor biology.  
ER-α variant ER-α36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells 期刊论文
Journal of Steroid Biochemistry and Molecular Biology, 2014, 卷号: 144, 期号: PART B, 页码: e417-e426
作者:  Deng H.;  Yin L.;  Zhang X.-T.;  Liu L.-J.;  Wang M.-L.
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/17

©版权所有 ©2017 CSpace - Powered by CSpace